Descartes-08 for adults with antisynthetase syndrome and dermatomyositis muscle inflammation
Tests Descartes-08 against placebo in adults with antisynthetase syndrome or dermatomyositis.
Key facts
- Who runs it
- Cartesian Therapeutics
- Where
- Austin, Boston, Chapel Hill, and Orange, United StatesSee the 4 sites
- Trial code
- Registry title
- Descartes-08 in Autoantibody Myositis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 28 Apr 2026
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Descartes-08
- Placebo
- Record updated
- 17 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dermatomyositis or antisynthetase syndrome that affects the muscles and/or skin. Their disease has not responded to standard therapy, or they could not tolerate it. Each person gets either Descartes-08 or a placebo.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Confirmed dermatomyositis (probability score ≥55% on the 2017 EULAR/ACR criteria) or antisynthetase syndrome (ACR/EULAR criteria). The disease must involve the muscles and/or skin. Blood, kidney, liver and lung function must be adequate (SpO₂ ≥92% on room air).
- Earlier treatment
- Disease did not respond to standard therapy, or the person could not tolerate it. Stable background immunosuppressive therapy for ≥8 weeks. No recent use of banned immune-suppressing drugs, biologics or study drugs, and no live vaccine within 4 weeks.
Main reasons for not taking part
- Lung disease (ILD) only, without muscle or skin involvement, or ILD that needs oxygen, severe lung problems (FVC ≤45%, DLCO ≤40%) or pulmonary hypertension
- Severe permanent muscle damage or advanced weakness, such as needing a wheelchair
- Other inflammatory muscle diseases, or other severe autoimmune, heart, lung or nerve-muscle diseases
- Pregnancy or breastfeeding
- Active or uncontrolled infections such as HBV, HCV, HIV or tuberculosis, inborn immune deficiency, or a past organ or bone marrow transplant
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Confirmed diagnosis of one of the following:; Dermatomyositis (DM): Probability score ≥55% on the 2017 EULAR/ACR (European Alliance of Associations of Rheumatology/ American College of Rheumatology) criteria for classification of dermatomyositis (corresponding to diagnosis of 'probable or definite' DM). OR Antisynthetase Syndrome (ASyS): Diagnosis based on ACR/EULAR Classification Criteria (1)."
- Participants must have dermatomyositis or antisynthetase syndrome with muscle and/or skin involvement
- Refractory or intolerance to standard therapy
- Stable background immunosuppressive therapy for ≥8 weeks
- Adequate hematologic, renal, hepatic, and pulmonary function (SpO₂ ≥92% on room air)
- Informed consent, compliance with visits, contraception, and vaccinations required
Who cannot take part
- Isolated interstitial lung disease (ILD) without muscle or skin involvement; Severe irreversible muscle damage or advanced weakness (e.g., wheelchair-bound); Interstitial lung disease (ILD) requiring oxygen, severe pulmonary impairment (FVC ≤45%, DLCO ≤40%), or pulmonary hypertension; Other inflammatory myopathies (PM, IMNM, IBM, cancer- or drug-induced myositis, overlap myositis except Sjögren's); Other severe neuromuscular, cardiac, pulmonary, or systemic autoimmune diseases requiring immunosuppression; Significant uncontrolled chronic illnesses or psychiatric conditions interfering with participation; Pregnancy or lactation; Recent use of prohibited immunosuppressants/biologics or investigational agents (per washout periods); Live vaccination within 4 weeks; History of primary immunodeficiency, organ or bone marrow transplant; Active or uncontrolled infections: HBV, HCV, HIV, tuberculosis, or recurrent/severe infections
Where in United States
- National Neuromuscular Research InstituteAustin, United StatesContact: Cartesian TherapeuticsTaking people
- Brigham and Women's HospitalBoston, United StatesContact: Cartesian TherapeuticsTaking people
- University of North CarolinaChapel Hill, United StatesContact: Cartesian TherapeuticsTaking people
- University of California IrvineOrange, United StatesContact: Cartesian TherapeuticsTaking people
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).
The 2 groups in the trial
- Decartes-08Treatment being tested
Treatment: Descartes-08
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome
- Plain-language title
- Descartes-08 for adults with antisynthetase syndrome and dermatomyositis muscle inflammationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 August 2026